• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在腹膜转移和细胞学结果背景下,血清和腹水中CEA及CA 19-9水平在结直肠癌患者中的意义

The Significance of CEA and CA 19-9 Levels in Serum and Peritoneal Fluid in Colorectal Cancer Patients in the Context of Peritoneal Metastases and Cytology Results.

作者信息

Bąk Michał, Wojciech Magdalena, Monczak Roman, Zawadzki Marek, Murawa Dawid

机构信息

General and Oncological Surgery, The Karol Marcinkowski University Hospital, 65-417 Zielona Góra, Poland.

Department of Surgery and Oncology, University of Zielona Góra, 65-417 Zielona Góra, Poland.

出版信息

Cancers (Basel). 2025 Aug 15;17(16):2661. doi: 10.3390/cancers17162661.

DOI:10.3390/cancers17162661
PMID:40867290
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12384164/
Abstract

BACKGROUND/OBJECTIVES: Colorectal cancer (CRC) frequently metastasizes to the peritoneum, significantly worsening patient prognosis. While serum tumor markers such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) are routinely measured, their diagnostic or prognostic role in peritoneal fluid remains unclear. This study aimed to assess the relationship between CEA and CA 19-9 levels in both serum and peritoneal fluid, and the clinical stage of CRC, particularly focusing on the presence of peritoneal metastases and positive cytology.

METHODS

We retrospectively analyzed data from 89 patients with histologically confirmed CRC who underwent surgery between 2020 and 2023. All patients had preoperative assessment of CEA and CA 19-9 levels in serum and peritoneal fluid, along with cytological examination of peritoneal fluid samples. Patients were categorized based on the presence or absence of macroscopic peritoneal metastases and cytology results.

RESULTS

Elevated levels of CEA and CA 19-9 in peritoneal fluid were significantly associated with the presence of peritoneal metastases. A positive cytological finding also correlated with higher marker concentrations.

CONCLUSIONS

CEA and CA 19-9 levels in peritoneal fluid strongly correlate with peritoneal dissemination in CRC. These markers may serve as additional predictive factors, aiding in early detection of peritoneal spread and improved risk stratification. Their assessment may be useful in guiding intraoperative and postoperative decision-making.

摘要

背景/目的:结直肠癌(CRC)常转移至腹膜,显著恶化患者预后。虽然癌胚抗原(CEA)和糖类抗原19-9(CA 19-9)等血清肿瘤标志物会常规检测,但它们在腹水中的诊断或预后作用仍不明确。本研究旨在评估血清和腹水中CEA和CA 19-9水平与CRC临床分期之间的关系,尤其关注腹膜转移和阳性细胞学检查结果的存在情况。

方法

我们回顾性分析了2020年至2023年间89例经组织学确诊的CRC手术患者的数据。所有患者术前均对血清和腹水中的CEA和CA 19-9水平进行了评估,并对腹水样本进行了细胞学检查。根据是否存在肉眼可见的腹膜转移和细胞学检查结果对患者进行分类。

结果

腹水中CEA和CA 19-9水平升高与腹膜转移的存在显著相关。阳性细胞学检查结果也与更高的标志物浓度相关。

结论

腹水中CEA和CA 19-9水平与CRC中的腹膜播散密切相关。这些标志物可作为额外的预测因素,有助于早期发现腹膜扩散并改善风险分层。它们的评估可能有助于指导术中及术后的决策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ead4/12384164/b8a78348213e/cancers-17-02661-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ead4/12384164/a56cdd48a7d1/cancers-17-02661-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ead4/12384164/b8a78348213e/cancers-17-02661-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ead4/12384164/a56cdd48a7d1/cancers-17-02661-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ead4/12384164/b8a78348213e/cancers-17-02661-g002.jpg

相似文献

1
The Significance of CEA and CA 19-9 Levels in Serum and Peritoneal Fluid in Colorectal Cancer Patients in the Context of Peritoneal Metastases and Cytology Results.在腹膜转移和细胞学结果背景下,血清和腹水中CEA及CA 19-9水平在结直肠癌患者中的意义
Cancers (Basel). 2025 Aug 15;17(16):2661. doi: 10.3390/cancers17162661.
2
Peritoneum carcinomatosis as a favourable prognostic factor for treatment with nanoliposomal irinotecan and fluorouracil plus leucovorin in advanced pancreatic cancer.腹膜癌病作为晚期胰腺癌采用纳米脂质体伊立替康与氟尿嘧啶加亚叶酸治疗的有利预后因素。
Ther Adv Med Oncol. 2025 Jun 26;17:17588359251351540. doi: 10.1177/17588359251351540. eCollection 2025.
3
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
4
Blood biomarkers for the non-invasive diagnosis of endometriosis.用于子宫内膜异位症无创诊断的血液生物标志物。
Cochrane Database Syst Rev. 2016 May 1;2016(5):CD012179. doi: 10.1002/14651858.CD012179.
5
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
6
Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?当前的生存预测工具在治疗骨转移后的骨骼相关事件时有用吗?
Clin Orthop Relat Res. 2024 Sep 1;482(9):1710-1721. doi: 10.1097/CORR.0000000000003030. Epub 2024 Mar 22.
7
Utility of serum CYFRA 21-1 as a prognostic biomarker in ALK-positive non-small cell lung cancer treated with ALK-TKIs: a retrospective cohort study.血清CYFRA 21-1作为ALK阳性非小细胞肺癌接受ALK-TKIs治疗的预后生物标志物的效用:一项回顾性队列研究。
Transl Lung Cancer Res. 2025 Jun 30;14(6):1986-2000. doi: 10.21037/tlcr-2024-1180. Epub 2025 Jun 26.
8
The Predictive Value of the Cholesterol-to-Natural Killer Cell Ratio in Colorectal Cancer.胆固醇与自然杀伤细胞比值在结直肠癌中的预测价值
J Cancer. 2025 Jun 23;16(9):2946-2958. doi: 10.7150/jca.114813. eCollection 2025.
9
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
10
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.

本文引用的文献

1
Liquid Biopsy and Challenge of Assay Heterogeneity for Minimal Residual Disease Assessment in Colon Cancer Treatment.液体活检与结肠癌治疗中微小残留病评估的检测异质性挑战
Genes (Basel). 2025 Jan 9;16(1):71. doi: 10.3390/genes16010071.
2
The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide.《2022年全球癌症统计报告》:数据来源、方法及全球癌症负担概述
Int J Cancer. 2025 Apr 1;156(7):1336-1346. doi: 10.1002/ijc.35278. Epub 2024 Dec 17.
3
The Advancement Stage of Gastric Cancer and the Levels of CEA and Ca19-9 in Serum and Peritoneal Lavage.
胃癌进展期与血清及腹腔灌洗中癌胚抗原(CEA)和糖类抗原19-9(Ca19-9)水平
Biomedicines. 2024 Nov 12;12(11):2584. doi: 10.3390/biomedicines12112584.
4
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据:全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
5
Prognostic significance of positive peritoneal cytology in endometrial carcinoma based on ESGO/ESTRO/ESP risk classification: A multicenter retrospective study.基于 ESGO/ESTRO/ESP 风险分类的子宫内膜癌阳性腹腔细胞学的预后意义:一项多中心回顾性研究。
Gynecol Oncol. 2023 Sep;176:43-52. doi: 10.1016/j.ygyno.2023.06.578. Epub 2023 Jul 11.
6
Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer.转移部位对转移性结直肠癌患者循环肿瘤DNA的影响。
JCO Precis Oncol. 2022 Apr;6:e2100535. doi: 10.1200/PO.21.00535.
7
Diagnostic Value of Tumor Markers in Peritoneal Lavage Fluid for Peritoneal Metastasis from Colorectal Cancer.腹腔冲洗液肿瘤标志物对结直肠癌腹膜转移的诊断价值。
Ann Clin Lab Sci. 2022 Jan;52(1):95-100.
8
Causes of Death After Colorectal Cancer Diagnosis: A Population-Based Study.结直肠癌诊断后的死亡原因:一项基于人群的研究。
Front Oncol. 2021 Mar 30;11:647179. doi: 10.3389/fonc.2021.647179. eCollection 2021.
9
Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer.恶性腹腔细胞学与 I 期子宫内膜样腺癌患者生存降低相关。
Eur J Cancer. 2020 Jul;133:33-46. doi: 10.1016/j.ejca.2020.03.031. Epub 2020 May 17.
10
Use of peritoneal washing cytology for the detection of free peritoneal cancer cells before and after surgical treatment of gastric adenocarcinoma.腹膜冲洗细胞学检查在胃腺癌手术治疗前后检测游离腹腔癌细胞中的应用。
J Cancer Res Ther. 2018 Oct-Dec;14(6):1225-1229. doi: 10.4103/0973-1482.184518.